Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ Innovative Medicine — D&A

Other segment segments

MEDTECH
$903M+8.0%
General Corporate
$65M+25.0%
Consumer Health
$0-100%

Similar metrics at other companies

Asset Entities logo
ASSTMedical Device — D&A
$32K—
AMP
AMPHPharmaceutical Products — D&A
$14.35M+5.4%
Novanta logo
NOVTMedical Solutions — D&A
$9.58M+24.7%
Opko Health logo
OPKPharmaceutical — D&A
$18.26M+2.7%
LKQ logo
LKQSpecialty — D&A
$8M0.0%
Axe Compute Inc. logo
AGPUDrug Discovery Services — D&A
$26.63K-78.0%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's innovative medicine — d&a.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's innovative medicine — D&A?
Johnson & Johnson (JNJ) reported innovative medicine — D&A of $1.04B in Q1 2026.
How has Johnson & Johnson's innovative medicine — D&A changed year-over-year?
Johnson & Johnson's innovative medicine — D&A increased by 17.2% year-over-year, from $884M to $1.04B.
What is the long-term trend for Johnson & Johnson's innovative medicine — D&A?
Over 4 years (2021 to 2025), Johnson & Johnson's innovative medicine — D&A has grown at a -1.6% compound annual growth rate (CAGR), from $4.03B to $3.77B.
What does innovative medicine — D&A mean?
This represents the non-cash expense allocated to the Innovative Medicine segment for the wear and tear of tangible assets and the systematic write-down of intangible assets over their useful lives. It reflects the capital intensity required to maintain the segment's R&D and manufacturing infrastructure. High levels often indicate significant historical investment in specialized pharmaceutical production facilities or acquired intellectual property.